Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
91-105 of 4097 results
Vaccinogen signs option deal with Dublin City University to acquire DiCAST platform
Vaccinogen has entered into an exclusive option agreement with Dublin City University (DCU), through one of its subsidiaries, that provides the company with an exclusive two-year option to evaluate and acquire a revolutionary high-throughput, multiplex, analysis platform – DiCAST.
Drug Research > Drug Discovery & Development > News
Certara and Paidion Research partner to improve pediatric drug development
Certara and Paidion Research have formed a partnership to promote more efficient and reliable drug development for pediatric patients.
Drug Research > Drug Discovery & Development > News
Audion Therapeutics secures funds to advance hearing loss treatment program
By PBR Staff Writer
Audion Therapeutics has secured funds to advance its lead program targeting sensorineural hearing loss to clinical proof of concept.
Drug Research > Drug Discovery & Development > News
AstraZeneca unveils further evidence for AZD9291 potential in first-line and pre-treated NSCLC
AstraZeneca has unveiled updated, encouraging data on AZD9291 (osimertinib) in first-line patients with epidermal growth factor receptor mutation (EGFRm) positive advanced non-small cell lung cancer (NSCLC) and previously treated patients with EGFR T790M mutation-positive NSCLC.
Drug Research > Drug Discovery & Development > News
Yabao and University of South Australia partner to develop new treatments for cancer
By PBR Staff Writer
China-based Yabao Pharmaceutical and the University of South Australia have collaborated to develop new treatments for cancer.
Drug Research > Drug Discovery & Development > News
Cleveland BioLabs wins deal for advanced development of Entolimod towards full licensure
By PBR Staff Writer
The Department of Defense (DoD) office of Congressionally Directed Medical Research Programs (CDMRP) Joint Warfighter Medical Research Program (JWMRP) has awarded Cleveland BioLabs (CBLI) a contract valued at up to $9.2m to support further development of entolimod as a medical radiation countermeasure.
Drug Research > Drug Discovery & Development > News
Novimmune signs international research collaboration deal with Baxalta
Novimmune has signed an international research collaboration agreement with Baxalta Incorporated to develop novel bispecific antibodies for an unspecified indication.
Drug Research > Drug Discovery & Development > News
QB3@953 signs collaboration agreement with GSK to identify early-stage drug discovery opportunities
QB3@953, a San Francisco incubator created by QB3, a University of California (UC) research institute and biotech accelerator, announced an agreement with pharmaceutical company GSK to identify and facilitate collaborations to translate early drug target concepts into medicines that benefit patients.
Drug Research > Drug Discovery & Development > News
Bristol-Myers, QIMR to discover new immuno-oncology antibodies
By PBR Staff Writer
Bristol-Myers Squibb (BMS) has entered into a research collaboration and license agreement with QIMR Berghofer Medical Research Institute for the discovery of new therapeutic antibodies against an undisclosed immuno-oncology (I-O) target.
Drug Research > Drug Discovery & Development > News
Soligenix gets additional NIAID funding to advance development of OrbeShield in GI ARS
Soligenix (SNGX), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised its option to advance preclinical development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP).
Drug Research > Drug Discovery & Development > News
Symic Biomedical gets $1.5m NIH Phase II SBIR grant to develop proteoglycan mimetic therapeutics
Platform therapeutic company Symic Biomedical (Symic) announced that it has received a $1.5m Phase II SBIR grant from the National Institutes of Health (NIH) to further develop its therapeutic agent to reduce arteriovenous fistula (AVF) failures, a significant unmet clinical need in end stage renal disease (ESRD) patients undergoing hemodialysis.
Drug Research > Drug Discovery & Development > News
Ironshore begins second Phase III trial of HLD-200 in pediatric ADHD patients
By PBR Staff Writer
Canada-based Highland Therapeutics' subsidiary Ironshore Pharmaceuticals has started dosing in the second of two pivotal trials of HLD-200, a next-generation formulation of methylphenidate for patients with attention-deficit/hyperactivity disorder (ADHD).
Drug Research > Drug Discovery & Development > News
HedgePath launches clinical trial for proposed cancer treatment
HedgePath Pharmaceuticals (HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced enrollment has commenced in its Phase II SCORING (SUBA-Cap Objective Response in Gorlin's) clinical trial.
Drug Research > Drug Discovery & Development > News
Vital Therapies' Phase III trial of ELAD System in patients with AILD failed to meet primary endpoint
Vital Therapies (VTL), a biotherapeutic company developing ELAD, a cell-based therapy targeting the treatment of liver failure, today announced that topline results from VTI-208, the Company's phase 3 randomized, controlled, open-label trial, evaluating the ELAD System in subjects with alcohol-induced liver decompensation (AILD) failed to meet the primary endpoint of overall survival through at least 91 days assessed using the Kaplan Meier statistical method.
Drug Research > Drug Discovery & Development > News
Roche and Janus partner to develop TLR inhibitor for autoimmune diseases
By PBR Staff Writer
Swiss drugmaker Roche has partnered with Janus Biotherapeutics to develop a small molecule toll-like receptor (TLR) inhibitor with the potential to address various autoimmune diseases.
Drug Research > Drug Discovery & Development > News
91-105 of 4097 results